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Abstract 
Background: Hepatitis C Virus (HCV) infection is a global epidemic with an estimated 71 million 
people infected worldwide. People who inject drugs (PWID) are over represented in prison 
populations globally and have higher levels of HCV infection than the general population. 
Despite increased access to primary health care while in prison, many HCV infected prisoners 
do not engage with screening or treatment. With recent advances in treatment regimes, HCV in 
now a curable and preventable disease and prisons provide an ideal opportunity to engage this 
hard to reach population.  
Aim: To identify barriers and enablers to HCV screening and treatment in prisons 
Methods: A qualitative study of four prisoner focus groups (n=46) conducted at two prison 
settings in Dublin, Ireland.  
Results: The following barriers to HCV screening and treatment were identified, lack of 
knowledge, concerns regarding confidentiality and stigma experienced and inconsistent and 
delayed access to prison health services. Enablers identified included; access to health care, 
opt-out screening at committal, peer support, and stability of prison life which removed many 
of the competing priorities associated with life on the outside. Unique blocks and enablers to 
HCV treatment reported were, fear of treatment and having a liver biopsy, the requirement to 
go to hospital and in-reach hepatology services and fibroscaning.  
Conclusion; The many barriers and enablers to HCV screening and treatment reported by Irish 
prisoners will inform both national and international public health HCV elimination strategies. 
Incarceration provides a unique opportunity to upscale HCV treatment and linkage to the 
community would support effectiveness.  
 
Introduction  
Hepatitis C infection (HCV) is a major global epidemic, with an estimated 71 million people 
chronically infected worldwide[1] . HCV carries a significant global disease burden with an 
estimated 399,000 dying annually from HCV related liver failure and cancer[1,2] . Unsafe 
injecting drug use (IDU) is the main route of HCV transmission in developed countries, with an 
estimated 20 million people who inject drugs (PWID) infected worldwide [2]. 
There are an estimated 10 million people incarcerated globally on any one day with many more 
coming in contact with the criminal justice system annually[2].  PWID are over represented in 
prison populations due to the criminalisation of drug use and the engagement in criminal 
activity to fund illicit drug habits [3,4]. A number of HCV transmissions risks in prisoners have 
already been reported in the literature these include unsafe IDU, sharing of drug taking 
paraphernalia, prison tattooing, and factors independent of these but linked to incarceration 
such as violent assault, sharing of tooth brushes and razors and possibly other unidentified 
factors[3,5–7] . There is also evidence in the literature of increased HCV transmission among 
HIV -infected men who have sex with men (MSM), which is a concern in prisons without access 
to condoms[8]. The incidence of HCV in general prison populations is estimated at 1.4 per 100 
person years (py), increasing to 16.4 per 100 py in inmates who inject drugs [3]. The global HCV 
prevalence in incarcerated populations is estimated at 26%, increasing to 64% among those 
with a history of IDU [3]. 
Prisoners have complex physical and psychological needs with poor access to and uptake of 
health services ([9,10]. While incarcerated, prisoners have better access to primary health care 
and lower mortality than when released back into the community [9,11] . Prison provides 
structured routine, access to good nutrition and exercise and removes many of the stressors 
experienced in the community [9]. HCV treatment can be effectively provided in prisons with 
outcomes equal or better than community based treatment [12,13]. Despite the recognised 
potential to screen and treat this high-risk group for HCV infection, uptake remains low [14]. 
The rate of imprisonment in Ireland is approximately 79 per 100,000 of population [15]. There 
are 3674 persons incarcerated in Ireland on any given day and the annual turnover of prisoners 
is 14,182[15]. In common with other prison populations , the majority  of inmates  are serving 
sentences of less than 12 months [15]. Similar to other prison populations globally, there are 
high levels of poverty, social deprivation, homelessness, early school dropout, unemployment, 
illiteracy, mental illness and drug use [4,6,9].  Over half of Irish  prisoners report a history of 
opiate use with 43 % reporting a history of injecting [6]. A 2000 study estimated the prevalence 
of HCV infection in the Irish prison population at 37% increasing to 81% % in those with a 
history of IDU [16].  A later study found a reduced HCV prevalence of 13% [6]. The Irish National 
HCV strategy (2014) identifies prisons as key locations to screen and treat HCV infection [17]. 
The Irish Prison Services (IPS) delivers primary health care through a network of general 
practitioners (GPs) and nurses in all 15 prison locations in the republic of Ireland (ROI). GPs and 
GP addiction specialist oversee blood borne virus (BBV) screening. Presently in Ireland there is 
no structured approach to HCV screening in prisons. National guidelines recommend that all 
prisoners should be tested for HCV infection [41] however no data is available on screening and 
treatment uptake in Irish prisons.  In-reach specialist hepatology services and fibroscanning 
services are provided in three prison locations in the Dublin area. These services provide HCV 
treatment equivalent to that provided in the community [18]. Direct acting anti-viral (DAA) 
therapies can only be prescribed by specialists and their costs are funded by the national health 
service (HSE) and does not impact on the prison health care budget.  
Barriers to HCV screening and treatment in the community have been previously identified [19–
21]. These include; lack of knowledge and awareness of HCV, substance misuse, mental illness, 
poor motivation, fear of treatment, fear of liver biopsy, competing priorities, rigid hospital 
appointment system, treatment eligibility criteria and  access, health insurance and 
transportation [19,21,22]. Similar blocks have been identified among prisoners [23,24] with 
other unique challenges have been described for prison populations. These include; short 
prison sentence, inter-prison transfers, prison bureaucracy and the cost to prison health care 
budgets. Critical enablers to HCV screening and treatment have been identified and these 
include, in-reach hepatology services, improved models of health care delivery, increasing 
prisoŶers͛ aǁareŶess aŶd uŶderstaŶdiŶg of HCV iŶfeĐtion and treatment options, educating 
both operational and clinical staff and involvement of peer educators in increasing knowledge 
and reducing stigma[25,26]. 
Similar to other developed countries, Ireland has a large cohort of untreated  chronically 
infected HCV prisoners [6,16]. New screening techniques (dried blood spot testing), liver 
disease screening tools(elastography) and drug therapies (DAA) have revolutionised HCV 
screening and treatment, both in the community and in prisons.[27–30] Many studies have 
identified barriers and enablers to community based HCV screening and treatment but very 
little research has been published on prison populations. HCV is now considered a preventable 
and curable infection but challenges remain to accessing those infected[11,31]. Prisons offer a 
unique opportunity to overcome these challenges and increasing prison-based screening and 
treatment is an essential public health strategy in tackling this global epidemic[32]. The aim of 
this study is to augment the existing scant published literature on blocks and enablers to prison 
HCV screening and treatment and inform the Irish National HCV treatment Program on 
strategies to maximise HCV screening and treatment uptake in the Irish prison population. 
Methodology  
The location of the study was The Mountjoy Campus in Dublin, Ireland and involved two of the 
three institutions. Mountjoy Prison is a closed, medium security prison for adult males with an 
operational capacity of 554. The Dochas Centre is a closed, medium security prison for adult 
females with an operational capacity of 105. Four focus groups took place during 2017. Ethical 
approval was granted by the Mater Hospital Ethics Committee as part of Seek and Treat 
component of The European Hep Care Project and ratified by the Irish Prison Services. 
Participants were recruited at both sites by open invitation through posters and directly by 
custodial and healthcare staff.  Focus groups were conducted onsite and in a room located in 
the medical section of each prison to ensure privacy. No inducements were offered for 
participation. On completion of the focus groups all participants were offered an opportunity to 
link with a specialist nurse.  All interested prisoners (n=46) were given a patient information 
sheet and a consent form to sign. Following, a review of the literature on the topic, completion 
of a scoping review and consultation with the research group and national experts in the area a 
focus group guide was finalised. This guideline included a series of open-ended questions 
covering the following areas; experience of community –based and prison- based HCV 
screening and treatment, barriers and enablers to uptake, challenges related to incarceration 
and release, inter-prison variations in health care delivery and role of security staff and peers in 
prison HCV management.  
Focus groups were facilitated by an experienced team of facilitators. Researcher 1 (DC) and 3 
(CM) facilitated focus group 1,2 and 4 (n= 37). Researcher 2 (MVH) and researcher 3 (CM) 
facilitated focus group 3 (n=9). The average time for the focus group was 75 minutes with a 
range between 45-90 minutes. The focus groups were recorded and the audio files were 
transcribed using Microsoft Word10 by researcher 1(DC). A grounded theory approach 
informed both the collection and analysis of the data. QSR NVivo 10.0 was used for organising 
and thematic coding of the transcribed data. The thematic coding was revised with the analysis 
of each focus group and analysis ceased when thematic saturation was achieved (agreed by 
researcher 1 and 2).  
Results 
The following themes related to barriers to both HCV screening and treatment emerged from 
the analysis; lack of knowledge, concerns regarding confidentiality, fear of being stigmatised, 
inconsistent access to prison health services with delays in screening and receiving results. 
Further themes related to enablers were identified including; access to health care, opt-out 
screening at committal, peer support, and stability of prison life which removed many of the 
competing priorities associated with life on the outside. Unique themes identified related to 
treatment included, fear of treatment and having a liver biopsy, the requirement to go to 
hospital and in-reach hepatology services and fibroscanning.  
Lack of knowledge  
All focus groups identified lack of knowledge as a major block to engagement with HCV 
treatment services.  Prisoners were aware of their own lack of knowledge and were often 
confused about the different types of hepatitis.  
 ͞I didŶ͛t kŶoǁ aŶǇthiŶg aďout it. I thiŶk I haǀe ;itͿ ďefoƌe I Đaŵe iŶ heƌe ďut I doŶ͛t kŶoǁ if it 
was Hep B or C͟. (male aged 28 years) 
͞You haǀe a high ƌisk of ĐatĐhiŶg it eǀeŶ if Ǉou͛ƌe Ŷot usiŶg it so I doŶ͛t kŶoǁ if it ǁas Hep C oƌ 
Hep B ……., there should be more education on it͟. (female aged 30 years) 
͞I ǁouldŶ͛t haǀe kŶoǁŶ aŶǇthiŶg aďout Hep C and we might be transferring it without knowing. 
EǀeƌǇoŶe should go aŶd haǀe a test doŶe ďeĐause Ǉou doŶ͛t haǀe to ďe oŶ dƌugs all the tiŵe foƌ 
that to happeŶ͟.  (male aged 33 years) 
͞I didŶ͛t kŶoǁ aďout the Hep till I came to Dublin a year ago and I heard ͚ďe Đaƌeful aďout the 
Hep͛ aŶd I ǁas like ǁhat the fuĐk is Hep͟. (female aged 24 years) 
Many prisoners were confused about modes of transmission. 
͞Think Ǉou ĐaŶ get it fƌoŵ sŵokiŶg a ƌollie oƌ fƌoŵ toilets. HaǀeŶ͛t got aŶǇ iŶfoƌŵatioŶ ͞. (male 
aged 28 years) 
͞Does it live for six months on the floor?͟ (male aged 22 years) 
Others commented on the misinformation that existed among other prisoners. 
͞The ŵisiŶfoƌŵatioŶ that͛s out theƌe. People thiŶk oŶĐe it͛s theƌe it͛s theƌe foƌ life like Ǉou͛ƌe 
riddled͟. (male aged 22 years) 
͞Most people ǁho doŶ͛t haǀe aŶ uŶdeƌstaŶdiŶg. You talk to soŵeoŶe ǁho saǇs soŵethiŶg theŶ 
Ǉou ask soŵeoŶe else aŶd theǇ͛d tell Ǉou a ĐoŵpletelǇ diffeƌeŶt stoƌǇ. “o, theƌe͛s 
ŵisiŶfoƌŵatioŶ. We still doŶ͛t kŶoǁ aŶǇthiŶg aďout it Ǉou kŶow͟. (female aged 24 years) 
Fear of liver biopsy and Treatment  
Many prisoners spoke about their fear of treatŵeŶt aŶd the ͞horror͟ stories they had heard 
from other inmates. Many found that their own experiences of treatment were much more 
positive, 
"Yeah, I heaƌd of people losiŶg theiƌ haiƌ. It͛d put Ǉou off. But it didŶ͛t affeĐt ŵe oŶe ďit the ǁaǇ 
I thought it would. Need more education on that part of it͟. (male aged 28 years) 
͞They used to get the injection but it made her sick or something. It did. She said she was very 
sick. Some people say I͛d rather die than do the treatment͟. (female aged 26 years) 
A number of prisoners described the fear of liver biopsy and similar to their experience found 
the reality of having the biopsy less onerous. 
͞I remember Ǉeaƌs ago theǇ͛d go iŶ thƌough the top of the shouldeƌ.  So, I ǁouldŶ͛t do it. Heaƌ 
people ͚doŶ͛t get that liǀeƌ ďiopsǇ͛ ďut I ǁeŶt thƌough it myself.... it was grand, no paiŶ͟.  (male 
aged 34 years) 
͚͞TheǇ͛ƌe goiŶg to hit Ǉouƌ luŶg͛ just sĐaƌeŵoŶgeƌiŶg͟. (male aged 27 years) 
Concerns regarding confidentiality  
Prisoners expressed concerns regarding confidentiality. Some believed that non-medical staff 
had access to their medical records. 
͞TheǇ ;pƌisoŶ offiĐeƌsͿ saǇ theǇ ǁoŶ͛t ĐheĐk ďut that͛s ďullshit Ǉou can go into any computer and 
access whatever you want͟. (male aged 28 years) 
Many explained that the process of being called for bloods and hospital appointments was not 
confidential and prisoners were often called on the landing for certain blood tests and hospital 
appointments which revealed their medical status to the other prisoners and security staff.  
͞Getting called for tests as you walk onto the landing aŶd theƌe Ǉou͛ƌe gettiŶg Đalled foƌ ďlood 
test aŶd people see Ǉou goiŶg aŶd saǇ ǁhǇ͛s he gettiŶg a ďlood test, ǁhǇ ǁhǇ ǁhǇ Ǉou kŶoǁ?͟ 
(male aged 34 years) 
Fear of being stigmatised  
Coupled with anxiety around confidentiality was the fear of being stigmatised by other 
prisoners and staff if they became aware of their HCV status. 
͞Theƌe͛s a stigŵa attaĐhed to it. Theƌe is!!͟ (female aged 25 years) 
͞TheŶ oŶe of theŵ Đalled ŵe aside ďeĐause it͛s goŶe aƌouŶd that I had the ǀiƌus. That͛s ǁhǇ I 
got sacked out of the kitchen because I had the virus.... Pure ignorance to take me out of the 
kitchen, just because I had Hepatitis C and at that stage it was gone͟. (male aged 36 years) 
͞Yeah definitely! TheǇ feel like theǇ͛ƌe goŶŶa get judge͟. (female aged 26 years) 
Many prisoners described a double stigma, the first associated with their HCV status and the 
second with being identified as a prisoner in a hospital setting. The policy of handcuffing male 
prisoners for security reason while attending out-patient appointments was identified as 
increasing the chances of experiencing stigma and shame. There appeared to be regional 
variation, with prisoner have more negative experiences in rural areas. 
͞WheŶ I ǁas iŶ the Joy (Mountjoy Prison) you͛d hate it ďeĐause you͛d haǀe ĐhaiŶs all oǀer you. 
HaŶdĐuffs aŶd that shit͟.  ;ŵale aged 26 yearsͿ 
͞IŶ DuďliŶ ǁheŶ you͛re ďrought to the hospital they͛re ŵore used to it. WheŶ you go into the 
hospitals iŶ the ĐouŶtry iŶ haŶdĐuffs eǀeŶ the doĐtors aŶd Ŷurses are lookiŶg at you͟. ;ŵale 
aged 34 years) 
͞Talking to me like a piece of shit, and this man was taking my bloods. It makes an awful lot of 
difference͟. (male aged 36 years) 
Systemic barriers  
Many participants expressed frustration at the many systemic blocks to HCV screening and 
treatment they experienced while incarcerated. These included delays in having bloods taken 
͞Could be months down the line and they forget about it and then they come out of nowhere͟. 
(male aged 29 years) 
͞Not Đhased up, it͛s Ŷot effiĐieŶt͟. (female aged 24 years) 
Many also experienced long delays in receiving the results once the blood was taken.  
͞I͛ǀe ǁaited tǁo aŶd a half Ǉeaƌs ďadgeƌiŶg foƌ results so again that happens even if you did ask 
it takes too long so need to move quicker͟. (male aged 29 years) 
͞TheǇ͛ƌe gettiŶg out ďefoƌe theǇ eǀeŶ get ďlood tests. TheŶ ǁheŶ Ǉou͛ƌe ĐoŵiŶg ďaĐk iŶ, theǇ͛ƌe 
doing the same tests again and again͟.  (male aged 36 years) 
Others felt they had to wait too long for treatment despite being motivated and willing to 
engage with services.  
͞Very slow process, to the point of treatment.  For me it took years. For me I wanted the 
treatment as soon as possible and it still took ages͟. (male aged 36 years) 
Enablers  
  Opt-out screening at committal  
Screening on comital was seen by most inmates as an enabler to treatment describing it as 
͞ŵore priǀate͟ aŶd ͞ŵore suitaďle ͞. “oŵe proposed aŶ opt-out type of screening program. 
͞Make it automatic, straight away when you come in on committal͟. ;ŵale aged 26 years) 
͞It should be done when you land in the prison. Should be just done͟.  (female aged 44 years) 
However, some participants were concerned that committal was already a stressful time for 
many inmates adapting to their new surroundings with some having to manage withdrawals. 
͞A ďig gƌoup to do eǀeƌǇoŶe theƌe aŶd theŶ people aƌe ĐoŵiŶg iŶ ǁith ǁithdƌaǁals ...  it͛s a 
diffiĐult situatioŶ foƌ us to ďe iŶ too. That͛s ǁhǇ they leave it for a while so people fit into the 
ƌoutiŶe. Although if Ǉou͛ƌe oŶlǇ ƌeŵaŶded foƌ a ǁeek Ǉou ǁouldŶ͛t get it͟. (male aged 34 years) 
In-reach hepatology  
Participants identified the presence of in-reach hepatology services at both locations as a 
facilitator to engagement with HCV treatment. The availability of on-site specialist hepatology 
reduced the need for patients to attend hospital outpatients. 
 ͞It͛d ďe ŵuĐh ďetteƌ if the seƌǀiĐes ǁeƌe iŶ the prison so Ǉou didŶ͛t eǀeŶ Ŷeed to go to hospital͟. 
(female aged 29 years) 
Access to in-reach fibroscanning 
The majority of prisoner expressed satisfaction with access to and the experience of 
fibroscanning. They desĐriďed it as ͞Ŷo proďleŵ͟ ͞just a sĐaŶ ͞aŶd ͞siŵple͟. They ideŶtified it 
as an enabler to screening and treatment.  
͞People go and get tested quicker͟.  (male aged 34 years) 
͞No hesitatioŶ at all, the ǁoŵaŶ that does it is ŶiĐe. “he eǆplaiŶs it all to Ǉou, she͛s good at 
talking simple͟.  (male aged 26 years) 
͞If people kŶoǁ it͛s ŶothiŶg ďig just a ďit of gel theŶ it͛s Ŷo pƌoďleŵ. WheŶ she shoǁed ŵe the 
machine it was no problem.  Everyone would jump on that a lot quicker. Test so easy to get 
done͟.  (male aged 28 years) 
Participants highlighted that they had quicker and easier access to fibroscanning within prison 
than in the community. 
͞It͛s haƌd to get aŶ appoiŶtŵeŶt oŶ the outside but it only takes 5-10 minutes in the (prison) 
ĐliŶiĐ. WheŶ Ǉou kŶoǁ it͛s that siŵple Ǉou͛ll go ϭϬ tiŵes ƋuiĐkeƌ thaŶ hospital͟. (female aged 24 
years) 
͞Outside like…if Ǉou haǀe aŶ appoiŶtŵeŶt Ǉou͛d put it off aŶd put it off. You͛ǀe ŶothiŶg ďut tiŵe 
in this place, It͛s easieƌ͟.  (male aged 32 years) 
Stability of prison life eliminating competing priorities  
All focus group participants agreed   that prison afforded and ideal opportunity to engage with 
HCV screening and treatment. Prison eliminated many of the blocks experienced by this cohort 
in the community in particular, homelessness, personal motivation, competing priorities, access 
to health care and drug treatment. 
͞I thiŶk Ǉou take the oppoƌtuŶitǇ ǁhile Ǉou͛ƌe heƌe iŶstead of.... EspeĐiallǇ ǁheŶ Ǉou͛ƌe iŶ 
prison͟. (female aged 28 years) 
͞You make excuses on the outside, make excuses about everything. In prison 100% you do it͟. 
(female aged 28 years) 
͞I͛ŵ iŶ jail Ŷoǁ I ďetteƌ get soƌted ... outside to get to the doctor, accommodation, drug use 
saŵe kiŶd of thiŶg if Ǉou͛ƌe Ŷot gettiŶg aĐĐoŵŵodatioŶ Ǉou͛ƌe Ŷot goiŶg to go to aŶǇ doĐtoƌ. 
No aĐĐoŵŵodatioŶ aŶd oŶ dƌugs Ǉou doŶ͛t Đhase aŶǇ of that up͟. (male aged 34 years) 
͞Every single time I got out, I go to nothing. I said it to welfare, when I get out of here I have 
Ŷoǁheƌe to go, I doŶ͛t ǁaŶt to get out aŶd go to ŶothiŶg. WalkiŶg aƌouŶd saǇiŶg stuff aŶd it͛s 
like with hospital appointments or aŶǇthiŶg Ǉou doŶ͛t thiŶk aďout it͟. (male aged 38 years) 
͞Hard enough for us to cope as it is outside with everyday life without throwing that on top. The 
oppoƌtuŶitǇ to do it iŶ pƌisoŶ Ǉou doŶ͛t haǀe all the stƌesses of life to go ǁith it, Ǉou͛ƌe ŵoƌe 
willing to take it on͟. (female aged 36 years) 
͞Yeah goiŶg ďaĐk out ǁith Ŷo addƌess Ǉou kŶoǁ... ǁalkiŶg doǁŶ the stƌeets, Ǉou just ǁouldŶ͛t 
go to hospital. Prison, quieter͟.  (female aged 25 years) 
 
Peer support  
Many participants identified peer educators as a potential facilitator to HCV screening and 
treatment. A number of prisoners had experienced mass HIV and TB screening programs 
involving Red Cross peer workers while serving previous sentences and described it as 
facilitating their engagement.  They described trusting the peers, in particular those prisoners 
who had completed HCV treatment.  
͞Someone ǁho͛s ďeeŶ thƌough it aŶd kŶoǁs aďout it aŶd kŶoǁs aďout the ďodǇ. “oŵeoŶe that͛s 
ďeeŶ thƌough it that͛s ďeeŶ through the treatment that understands it͟. (male aged 28 years) 
͞It is helpful ǁheŶ Ǉou͛ƌe talkiŶg to soŵeoŶe like that aŶd theǇ kŶoǁ ǁhat theǇ͛ƌe talkiŶg 
aďout, it͛s ĐoŵfoƌtiŶg͟. (male aged 34 years) 
͞Yeah fƌoŵ a pƌisoŶeƌ to a pƌisoŶeƌ. It͛s Ŷot like Ǉou͛ƌe goiŶg to ďe a teaĐheƌ giǀiŶg a leĐtuƌe. 
You͛ƌe just sittiŶg doǁŶ talkiŶg aďout hoǁ Ǉou ĐatĐh it aŶd just eduĐatiŶg people͟. (female aged 
27 years) 
 ͞Prisoners would give more time to other prisoners. You lose track with nurses because you just 
get fed up soŵetiŵes Wheƌe if it Đaŵe fƌoŵ a pƌisoŶeƌ ǁho had it Ǉou͛d listeŶ ŵoƌe ďeĐause 
Ǉou ƌelate to ǁhat theǇ͛ƌe afteƌ goiŶg thƌough so at least Ǉou͛d haǀe a ďit ŵoƌe uŶdeƌstaŶdiŶg 
at the eŶd of the daǇ ďeĐause Ǉou kŶoǁ theǇ͛ƌe Ŷot judgiŶg Ǉou͟. (female aged 28 years) 
Discussion 
Many of the barriers  to HCV screening and treatment in prisoners identified in this study have 
been reported previously in earlier studies conducted in the pre-DAA era [23,24]. As outlined in 
the introduction these include, lack of knowledge and awareness of HCV, poor motivation, fear 
of treatment, liver biopsy and stigma, competing priorities and prison bureaucracy.  Lack of 
information regarding HCV and its management and fear of treatment are recognised as 
challenges to HCV elimination in PWID and prisoners[19,23]. Much of the fear surrounding 
treatment is related to interferon-based therapies and the historical requirement for pre-
treatment liver biopsy[33]. Pan-genotypic DAA and non-invasive mobile elastography have 
simplified HCV treatment[34,35]. The findings from this study, the first conducted on this issue 
in the DAA era, supports the need for a program of education to disseminate this information 
among PWID and prisoners, who still report fear as a barrier to engagement.  
Participants identified peer-educators as a facilitator to engagement with health services while 
incarcerated and important sources to access health information. The importance of peer to 
peer education is well documented[36] . Peer education has been adopted in health promotion 
in various settings because of its cost-effectiveness over professionally delivered services [37]. 
Furthermore, peers are seen by other prisoners as a credible source of information and have 
the potential to address the lack of HCV related knowledge and stigma reported among prison 
populations [37].  
Study participants experienced delays in accessing HCV screening and in receiving results. It is 
recognised that HCV screening programs in prisons are often ad hoc, inconsistent and 
incomplete[38–41].. This research found an inconsistent approach to HCV screening with many 
prisoners only being tested at their own request. Consideration should be given to introducing 
an opt- out screening program on committal to prison in Ireland [39–41]. This  screening 
strategy has been shown to be  cost effective and has the potential to reduce HCV transmission 
and HCV related liver disease primarily in the community  [39,42]. It was also supported by 
many of the focus group participants. Importantly it has the potential to reduce stigma[40,43]. 
There was widespread support for opt-out screening at committal from the participants. The 
routine and structured nature of the committal process was seen as a means to embed HCV 
screening as a routine part of prison health care. A small number of participants expressed 
concerns about adding screening into an already stressful time for new committals that might 
be struggling with withdrawal symptoms. This concern has been reported previously in the 
literature[39,44].  
Research shows prison based HCV treatment to have equivalent or better outcomes to 
community and hospital- based treatment if the prisoner was not released or transferred 
during treatment [12,30]. Despite their high cost, the use of DAAs in prison populations, are 
shown to be cost effective[45]. In Ireland in-reach hepatology services exists in three 
institutions and two of these are included in this study. Prisoners identified these services as 
enablers to screening and treatment. These services reduce the need for hospital 
appointments, save on prison escorts, reduce risk to the general population and the 
embarrassment and stigma experienced by prisoners when attending these services while hand 
cuffed. In Ireland, the handcuffing of patients for hospital visits only occurs in the male prison 
population. In this study the female prison focus group did not experience the same stigma and 
embarrassment as their male counterparts when attending for hospital appointments, with 
ŵaŶy eŶjoyiŶg ͞ the day out͟ as ďreak froŵ the ŵoŶotoŶy aŶd ďoredoŵ of prisoŶ life. 
Reviewing this policy may have an impact on compliance and uptake of HCV treatment.  
Consideration should be given to piloting in an Irish setting other prison HCV treatment delivery 
models, shown to be effective in other jurisdictions. These include, nurse led clinics, 
teleconferencing and upskilling prison general practitioners and addiction doctors[46–48].  
Different models may work best for different prisons depending on HCV prevalence, the 
structure and skill set of local health care teams and the availability and relationships with 
specialist hepatology services. 
Any HCV screening and treatment model adopted by the IPS needs to take into consideration 
the need for continuity of treatment in the event of an inter-prison transfer or community 
release both identified as barriers to completing HCV treatment. Prisoners are often released 
without notice or pre-release planning. Linking community and prison in-reach hepatology will 
reduce the risk of patient drop-out on release. Inter-prison transfers need to be organised in a 
way that ensures prisoners on HCV treatment are only transferred to prisons where their 
treatment can be continued. Continuity  of treatment is a key component to the cost-
effectiveness of active case finding  and treatment in prisons and transitioning back to the 
community is now considered a high risk period for HCV transmission in prisons[49].   Focus 
group participants described the negative impact that transition back to the community with 
homelessness, unemployment, drug user and other competing impacts can have on HCV 
treatment compliance. HCV treatment is seen as a relative need and often not the most 
pressiŶg iŶ PWID͛s life iŶ the ĐoŵŵuŶity[50] 
A consistent theme expressed in all the focus groups was the stigma and shame felt by many of 
the prisoners who were HCV infected or had a history of drug use. This is well recognised in the 
literature [19,23,51].  Repeated concerns were voiced in the focus groups around 
confidentiality. Many prisoners believed that prison officers had access to their computerised 
health records. Some prisoners identified that having bloods taken or seeing certain staff 
members linked with hepatology services identified them among their fellow prisoners as drug 
users. Prisoners described being publicly called on their landings for certain appointments 
which were clearly associated with being assessed or treated for HIV/HCV infection. Many HCV 
infected patients are also in receipt of methadone maintenance treatment (MMT). The 
provision of MMT in both study locations is a large daily operational exercise making it 
impossible to protect the confidentiality of those attending the services. Maintaining absolute 
confidentiality is difficult in prison settings[52,53]. Despite such limitations every effort should 
be made to ensure medical confidentiality by educating and training of both clinical and non-
clinical staff on the issue and having appropriate information sheets for prisoners on how their 
medical records are stored and who has access to them. 
All participants favoured peer worker involvement in HCV management in Irish prisons. Peer 
educators are often used in prison setting to deliver education and training programs[54]. The 
model has also been shown to be effective in increasing HCV screening and treatment in 
community settings.[22,28] . Research shows high levels of satisfaction among service users and 
staff in community-based drug treatment clinics with this role[55]. There is further evidence to 
suggest that engagement in HCV care may be facilitated by the influence of peers who 
completed treatment [56]. The ETHOS Study in Australia reported a very strong positive 
response to peer workers by staff and service users which lead to improved access to services, a 
more client-friendly treatment environment and increased support to services users with 
assessment and engagement with HCV treatment [56]. Involving peer educators helps to dispel 
many of the myths regarding HCV treatment. It is also a very effective vehicle to develop 
education programs around HCV infection and treatment options. Peers can also be an 
effective support system for patients on treatment particularly in prison settings where 
traditional family and community support structures are absent. Many of the focus group 
participants identified the presence of a peer support network as an enabler to HCV screening 
and treatment.   
The strength of this study is that we were able to evaluate how different groups discussed HCV 
together and how they debated the merits and weaknesses of identified blocks including their 
own experiences. The use of the focus group methodology allowed for the engagement of large 
numbers of prisoners with limited use of prison staff. This is an important consideration for any 
research conducted in real-life prison settings with limited staff resources and competing 
priorities.  The engagement of both male and female prisoners was identified as a strength and 
increased the generalisablity of the findings both nationally and internationally.  There are a 
number of limitations to this study including; participants may not have revealed their 
complete HCV narrative in the presences of others, researcher 1 was known to the male 
participants and the involvement of only two of the 15 prisons located in the ROI. Apart from 
age and gender other demographics on focus group participants were not collected. Knowledge 
of incarceration and drug use history along with HCV status and treatment history of the 
participants could have increased the interpretation and understanding of the focus group 
narratives.  While the focus groups were conducted in only two locations, many of the 
participants had experience of other prisons and contributed these during the interviews. This 
may increase the generalisablity of the findings to prisons outside of Dublin.  
Conclusion  
Irish prisons are a key setting to identify and treat HCV infected PWID. This important public 
health strategy can only be achieved by the elimination of identified barriers to HCV screening 
and treatment in Irish Prisons. The availability of short-acting, tolerable and highly effective 
DAA can eliminate many of these barriers but effective education programs highlighting the 
benefits of these treatments are required. Expanding the provision of HCV treatment to non-
specialist health services such as general practitioners, within the prison and community, has 
the potential to increase HCV treatment uptake and outcomes.  Opt-out screening at committal 
with engagement of peer educators has the potential to increase engagement but to maximise 
treatment uptake it is imperative that pre-treatment assessment and treatment is offered as 
early as possible in the sentence to optimise completion and outcomes. The expansion of in-
reach hepatology services and peer -educators to all prisons in the ROI should be considered. 
This research identified the fear of stigma as a major barrier to engagement with HCV 
treatment. Efforts to upscale training and education among security and health care prison staff 
are required. At a broader policy level consideration should be given to the de- criminalisation 
of drug users and the development of health services underpinned by inclusion and acceptance. 
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